High affinity integrin polypeptides and uses thereof
AssigneeThe General Hospital Corporation
InventorsM. Amin Arnaout, Rui Li, Jian-Ping Xiong
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe General Hospital Corporation
InventorsM. Amin Arnaout, Rui Li, Jian-Ping Xiong
Estimating the term…
Polypeptides comprising all or part of a variant integrin α subunit A domain or a variant integrin β subunit A-like domain are described. In solution or in membrane-associated form, the A domain or the A-like domain of the polypeptides of the invention exists predominantly in a high affinity conformation. In the polypeptides of the invention, referred to as variant integrin polypeptides, a crucial isoleucine residue (described in greater detail below) is absent. The isoleucine can be either deleted or replaced with different amino acids residue, preferably a smaller or less hydrophobic amino acid residue, e.g., alanine or glycine. Because the variant integrin polypeptides of the invention exist in solution or in membrane-associated form predominantly in a high affinity conformation, they are useful in screening assays for the identification of molecules that bind to (and/or mediate the activity of) an integrin. They are also useful for generating antibodies, e.g., monoclonal antibodies, which bind to the high affinity form of an integrin. Some such antibodies recognize an epitope that is either not present or not accessible on an integrin that is in a lower affinity conformation. The variant integrin polypeptides of the invention can be derived from any integrin α subunit or any integrin β subunit and could be used therapeutically. The variant integrin polypeptides preferably include a ligand-binding portion of an A-domain or an A-like domain.
An isolated nucleic acid molecule encoding a variant CD11b α subunit having the Ile at position 332 replaced with an amino acid selected from Gly and Ala.
A isolated nucleic acid molecule encoding a polypeptide consisting of amino acids 144 to 331 of CD11b α subunit.
An isolated nucleic acid molecule encoding a polypeptide comprising amino acids 144 to 332 of CD11b α subunit wherein the Ile at amino acid 332 has been replaced by an amino acid selected from Gly and Ala.
A polypeptide comprising amino acids 144 to 332 of CD11b α subunit wherein the Ile at position 332 has been replaced by an amino acid selected from Gly and Ala.
A polypeptide comprising amino acids 144 to 331 of CD11b α subunit, the polypeptide not comprising amino acids 332 to 1152 of CD11b.
An isolated nucleic acid molecule encoding a variant CD11a α subunit having the Ile at position 331 replaced with an amino acid selected from Gly and Ala.
An isolated nucleic acid molecule encoding a polypeptide consisting of amino acids 144 to 330 of CD11a α subunit.
An isolated nucleic acid molecule encoding a polypeptide comprising amino acids 150 to 331 of CD11a α subunit wherein the Ile at amino acid 331 has been replaced by an amino acid selected from Gly and Ala.
A polypeptide comprising amino acids 150 to 331 of CD11a α subunit wherein the Ile at position 331 has been replaced by an amino acid selected from Gly and Ala.
A polypeptide comprising amino acids 150 to 330 of CD11a α subunit, the polypeptide not comprising amino acids 331 to 1223 of CD11a.
A method for determining whether a test compound is a candidate compound for binding to CD11b, comprising:
A method for determining whether a test compound is a candidate compound for binding to CD11a, comprising:
Dependencies are inferred from the claim text.